Abstracts tagged "risk assessment"

Abstract Number: 1518 • ACR Convergence 2024
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Maria Cuellar-Gutierrez¹, Jaime Flores Gouyonnet¹, Gabriel Figueroa-Parra², Marta Casal Moura¹, Fernando C. Fervenza¹, Andrew C. Hanson³, Cynthia Crowson¹, Sanjeev Sethi¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Mayo Clinic, Rochester
Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
Abstract Number: 2340 • ACR Convergence 2024
Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
Jessica A Walsh¹, Shaobo Pei², Gopi Penmetsa³, Swetha Alexander⁴, Nga Lori Ly⁵, Rosario Adriana Molano-Romero⁴, April Conlon⁶, Catherine Bakewell⁷, Soumya Reddy⁸, Jose Scher⁹ and Alexis Ogdie¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²University of Utah, Thousand Oaks, CA, ³University Of Utah Hospital, Salt Lake City, UT, ⁴University of Utah Health, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Utah, Sandy, UT, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸NYU Grossman School of Medicine, New York, NY, ⁹New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diagnostic delays are common in psoriatic arthritis (PsA). Screening surveys administered in clinic can identify psoriasis patients at elevated risk for PsA who should…
Abstract Number: 0694 • ACR Convergence 2024
A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database
Stefano Di Donato¹, Michael Hughes², John Pauling³, Marco Matucci-Cerinic⁴, Lesley-Anne Bissell⁵, Edward Jude⁶, Christopher Denton⁷, Yannick Allanore⁸, Marie-Elise Truchetet⁹ and Francesco Del Galdo¹⁰, and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴University San Raffaele Milano, Milano, Milan, Italy, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸Université Paris Cité, Paris, France, ⁹Bordeaux University Hospital, Bordeaux, France, ¹⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Vascular dysfunction is pivotal in Systemic Sclerosis (SSc) pathogenesis, leading to somatic vascular signs such as pitting scars, Digital Ulcers (DUs), telangiectasia as well…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 2389 • ACR Convergence 2024
Choroidal Thickness in Active Lupus Nephritis
Leticia Maria Kolachinski R Brandao¹, Lucas Parente de Andrade², Débora Cordeiro do Rosário³, Paula Letícia De Queiroz e Barbosa⁴, Francisco Formiga³, Carolina Torres Ribeiro⁵, Tatiana do Nascimento Pedrosa³, Maria Fernanda Abalem de Sá Carricondo⁶, Pedro Carlos Carricondo², Eloisa Bonfa³ and Michelle Remiao Ugolini Lopes³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Campinas, SP, Brazil, ²Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, ⁵Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁶Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Lupus choroidopathy was reported to be a marker of severe systemic lupus erythematosus (SLE) activity, commonly associated with nephropathy. However, it remains controversial if…
Abstract Number: 0695 • ACR Convergence 2024
Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Stefano Di Donato¹, Marco Minerba², Enrico De Lorenzis³, Collette Hartley⁴, Lesley-Anne Bissell⁵, Rebecca Ross⁶ and Francesco Del Galdo⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Campus Bio-Medico University of Rome, Taranto, United Kingdom, ³Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
Abstract Number: 1614 • ACR Convergence 2024
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez-Álvaro², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maite Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael Gonzalez⁷, Julio Sánchez-Martín⁸, Javier Narvaez-García⁹, Joan Calvet¹⁰, Ivette Casafont-Solé¹¹, José A Román Ivorra¹², Selene Labrada-Arrabal¹³, Margarida Vasques Rocha:¹⁴, Carlota L Iñiguez:¹⁵, Maria Sagrario Bustabad Reyes¹⁶, Cristina Campos-Fernández¹⁷, María Alcalde Villar:¹⁸, Antonio Juan-Mas¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Ourense, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, ⁷Complejo Asistencial Universitario de Leon, León, Spain, ⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valencia, Spain, Valencia, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital Universitario Araba, Vitoria, Spain, ¹⁵Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁶Hospital Universitario de Canarias, La Laguna - Tenerife, Spain, ¹⁷Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ¹⁸Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Mallorca, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: The question of survival in epidemiologic studies on giant cell arteritis (GCA) remains unclear to date, with notable heterogeneity in both the mortality rate…
Abstract Number: 2399 • ACR Convergence 2024
Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization
Simran Bhimani¹, Anand Maligireddy², Shivang Chaudhary³, Yash Deshpande², Kishan Patel⁴, Sameer Bhimani², Shreyas Patel² and Birju Bhatt⁵, ¹The Wright Center for graduate medical education, Scranton, PA, ²The Wright Center, GME, Scranton, PA, ³Saint Louis University, St. Louis, MO, ⁴Riverside Community Hospital, Riverside, CA, ⁵Geisinger, Wilkes Barre, PA
Background/Purpose: Ischemic stroke poses significant risks for patients with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), both conditions associated with heightened cardiovascular complications. Endovascular…
Abstract Number: 0268 • ACR Convergence 2023
Safety and Efficacy of CT-guided Percutaneous Infra-Renal Periaortic Biopsies in Suspected Retroperitoneal Fibrosis
Cody Anderson, Max Guarda, Umar Ghaffar, Thomas Atwell, Kenneth Warrington, Michael Moynagh and Matthew Koster, Mayo Clinic, Rochester, MN
Background/Purpose: Retroperitoneal fibrosis (RPF) commonly affects the infrarenal abdominal aorta (irAA) and manifests with periaortic soft tissue thickening (pASTT). RPF can be either idiopathic (primary)…
Abstract Number: 1445 • ACR Convergence 2023
SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort
Iñigo Rúa-Figueroa¹, Maria Jesus Garcia de Yebenes², JULIA MARTINEZ BARRIO³, Maria Galindo-Izquierdo⁴, Jaime Calvo- Alén⁵, Antonio Fernandez-Nebro⁶, Raúl Menor-Almagro⁷, Eva Tomero Muriel⁸, Mercedes Freire González⁹, Clara Sanguesa Gomez¹⁰, Loreto Horcada¹¹, Ricardo Blanco¹², Esther Uriarte Isacelaya¹³, Maria J. García-Villanueva¹⁴, Javier Narvaez¹⁵, Jose Rosas¹⁶, Silvia Gómez-Sabater¹⁷, Clara Moriano Morales¹⁸, Jose Luis Andreu-Sánchez¹⁹, Vicente Torrente-Segarra²⁰, Elena Aurrecoechea Aguinaga²¹, Ana Pérez Gómez²², Javier Novoa Medina²³, Eva Salgado-Pérez²⁴, Nuria Lozano Rivas²⁵, Carlos Montilla-Morales²⁶, maria esther ruiz-lucea²⁷, Marta Arévalo Salaet²⁸, Carlota Iñíguez²⁹, Lorena Expósito³⁰, Mónica Ibáñez-Barceló³¹, Gema Bonilla³², Irene Carrión-Barberà³³, Celia Erausquin³⁴, Angela Pecondon-Español³⁵, Francisco Javier Toyos Sáenz de Miera³⁶, Tatiana Cobo³⁷, Alejandro Muñoz³⁸, Jorge Juan Fragio³⁹, Jose Eloy Oller⁴⁰, Beatriz Tejera Segura²³ and Jose-Maria Pego-Reigosa⁴¹, ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²InMusc, Madrid, Spain, ³Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁴Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁵Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁰Severo Ochoa Hospital, Madrid, Spain, ¹¹Hospital de Navarra, Pamplona, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹³Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Hospital Marina Baixa, Alicante, Spain, ¹⁷Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹⁸Rheumatology, Hospital Universitario de León, León, Spain, ¹⁹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁰Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ²¹Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²²Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²³Complejo Hospitalario Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁴Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ²⁵Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁶Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²⁷Hospita de Basurto, Bilbao, Spain, ²⁸Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, ²⁹Hospital Lucus Augusti, Lugo, Spain, ³⁰Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, ³¹Rheumatology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ³²Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ³³Hospital del Mar, Barcelona, Spain, ³⁴Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁵Hospital Miguel Servet, Zaragoza, Spain, ³⁶Hospital Virgen Macarena, Sevilla, Spain, ³⁷Department of Rheumatology, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ³⁸Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ³⁹Hospital General Universitario Valencia, Valencia, Spain, ⁴⁰Hospital Doctor Peset, Valencia, Spain, ⁴¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of serious infections that varies with the severity of the disease, use of immunosuppressives,…
Abstract Number: 0292 • ACR Convergence 2023
Comparison of Cardiovascular Risk of Myositis Patients and the General Population
Sabina Oreska¹, Hana Storkanova¹, Jaroslav Kudlicka², Vladimir Tuka², Ondrej Mikes², Zdislava Krupickova², Martin Satny², Eva Chytilova², Jan Kvasnicka², Maja Spiritovic³, Barbora Hermankova⁴, Petr Cesak⁵, Marian Rybar⁶, Karel Pavelka¹, Ladislav Senolt⁷, Herman Mann⁸, Jiri Vencovsky¹, Michal Vrablik² and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁵Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁶Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, ⁸Institute of Rheumatology, Praha 2, Czech Republic
Background/Purpose: Cardiovascular (CV) risk due to accelerated atherosclerosis and impaired metabolism can be increased in idiopathic inflammatory myopathies (IIM) on behalf of systemic inflammation, limited…
Abstract Number: 1486 • ACR Convergence 2023
Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)
Hamza Liaqat¹, Muhammad Qureshi², Awais Farooq³, Mashal Awais², Amar Patel⁴ and Aisha Barlas⁵, ¹Wah Medical College, Wah Cantt, Pakistan, ²Southeast Health Internal Medicine Residency Prog., Dothan, AL, ³University of Illinois Chicago, Chicago, IL, ⁴Texas Tech University Health Sciences Center, El paso, TX, ⁵Mercy Health, Rockford, IL
Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).Methods: Patient data was collected for years…
Abstract Number: 0387 • ACR Convergence 2023
The Association Between Inflammation, High-Sensitivity Cardiac Troponin T, and Cardiovascular Events in Rheumatoid Arthritis
Brittany Weber¹, Dana Weisenfeld¹, Mary Jeffway¹, Jonathan Coblyn¹, Michael Weinblatt², Nancy Shadick³, Marcelo DiCarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Waban, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 1.5x excess risk of cardiovascular (CV) disease compared to the general population, attributed to chronic inflammation. In…
Abstract Number: 1604 • ACR Convergence 2023
First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Yasaman Ahmadzadeh², Danieli Andrade³, leslie skeith⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Denis WAHL¹⁴, Maria Gerosa¹⁵, Guilherme De Jesús¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Laura Andreoli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁷, Guillermo Pons-Estel²⁸, Rohan Willis²⁹, Ali Duarte-Garcia³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Doruk Erkan¹ and On Behalf Of APS ACTION³³, ¹Hospital for Special Surgery, New York, NY, ²Roger Williams Medical Center, Providence, RI, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Milan, Milano, Italy, ¹⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷University of Michigan, Ann Arbor, MI, ²⁸CREAR, Rosario, Argentina, ²⁹University of Texas Medical Branch, Galveston, TX, ³⁰Mayo Clinic, Rochester, MN, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³on behalf of APS ACTION, New York, NY
Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…
Abstract Number: 0388 • ACR Convergence 2023
Left Ventricular Geometry Abnormalities Are Related to Higher Clinical Activity in Rheumatoid Arthritis Patients
Victor Beltran¹, Iris Colunga², Dionicio A. Galarza-Delgado², José Ramón Azpiri-López², Jesus Alberto Cardenas-De la Garza³, Rosa Arvizu-Rivera⁴, Valeria Gonzalez-Gonzalez⁵ and Angel Arias Peralta⁶, ¹Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) leading cause of death is cardiovascular (CV) disease. RA patients can develop silent myocardial tissue alterations, which result in changes in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.